Real-world comparative effectiveness of FOLFOX, FOLFIRI, and CapOx as second-line chemotherapy for advanced biliary tract cancer
Vergleich der Wirksamkeit von FOLFOX, FOLFIRI und CapOx in der Zweitlinientherapie des fortgeschrittenen biliären Traktskarzinoms
The Oncologist · 07.10.2026 · 31 (11)
DOI: 10.1093/oncolo/oyag424 ↗Auf einen Blick
Bei fortgeschrittenem BTC waren FOLFOX, FOLFIRI und CapOx in der Zweitlinientherapie mit vergleichbarem Gesamtüberleben und ähnlicher Toxizität verbunden.
Fragestellung
Vergleich der Wirksamkeit und Sicherheit von FOLFOX, FOLFIRI und CapOx als Zweitlinienchemotherapie bei fortgeschrittenem biliärem Traktskarzinom.
Methode
Beobachtungsstudie aus dem TriNetX Global Collaborative Network mit Erwachsenen mit fortgeschrittenem BTC nach First-line-Gemcitabin plus Cisplatin; Vergleich der Zweitlinienregime zwischen Januar 2010 und Juli 2025; 1:1 Propensity-Score-Matching.
Ergebnisse
825 erhielten FOLFOX, 184 FOLFIRI und 149 CapOx; nach Matching 182 und 149 je Gruppe. Medianes OS war zwischen FOLFOX und FOLFIRI vergleichbar (5,7 vs. 5,8 Monate; P = .958) und zwischen FOLFOX und CapOx (5,7 vs. 5,8 Monate; P = .803).
Schlussfolgerung der Autor:innen
Die Autoren berichten vergleichbare Überlebensausgänge unter FOLFOX, FOLFIRI und CapOx als Zweitlinientherapien für fortgeschrittenes BTC und unterstützen eine individualisierte Regimewahl nach Patientenmerkmalen und Toxizität.
Kernaussagen
- Medianes OS: 5,7 vs. 5,8 Monate in beiden Vergleichen
- Gesamt-Toxizität war zwischen den Regimen vergleichbar
- FOLFOX: weniger Neutropenie als FOLFIRI, aber mehr Thrombozytopenie
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Vergleichsstudie in der Zeitschrift The Oncologist, online erschienen am 21.10.2026. Verfasst von Chun-Yang Chao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital, Taichung 407219, Taiwan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Advanced biliary tract cancer (BTC) has a poor prognosis following progression on first-line gemcitabine plus cisplatin. However, evidence comparing second-line chemotherapy regimens remains limited. This study aimed to compare the effectiveness and safety of fluorouracil, leucovorin, and oxaliplatin (FOLFOX); fluorouracil, leucovorin, and irinotecan (FOLFIRI); and capecitabine plus oxaliplatin (CapOx). Patients and Methods Adults with advanced BTC who received first-line gemcitabine plus cisplatin followed by second-line FOLFOX, FOLFIRI, or CapOx between January 2010 and July 2025 were identified from the TriNetX Global Collaborative Network. Patients who subsequently received molecularly targeted therapies were excluded. The study included 825 patients receiving FOLFOX, 184 receiving FOLFIRI, and 149 receiving CapOx; after 1:1 propensity score matching, the respective comparisons included 182 and 149 patients per group. Overall survival (OS) and treatment-related adverse events were compared between the matched cohorts.
Results
The median OS was comparable between FOLFOX and FOLFIRI (5.7 months vs 5.8 months, P = .958) and between FOLFOX and CapOx (5.7 months vs 5.8 months, P = .803). The overall adverse event profiles were also comparable. However, FOLFOX was associated with lower rates of neutropenia but higher rates of thrombocytopenia than FOLFIRI. In contrast, FOLFOX and CapOx demonstrated similar toxicity despite modest differences in anemia and thrombocytopenia.
Conclusion
This real-world study demonstrates comparable survival outcomes among FOLFOX, FOLFIRI, and CapOx as second-line chemotherapies for advanced BTC. These findings support individualized regimen selection based on patient characteristics and toxicity profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402202, Taiwan.
- Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung 402306, Taiwan.
ORCID-Profile: Chun-Yang Chao, Kuan-Yu Tseng, Hsin-Chen Lin, Yu-Hsuan Shih
Zitieren
APA
Chao, C. Y., Tseng, K. Y., Lin, H. C., & Shih, Y. H. (2026). Real-world comparative effectiveness of FOLFOX, FOLFIRI, and CapOx as second-line chemotherapy for advanced biliary tract cancer. The Oncologist, 31(11). https://doi.org/10.1093/oncolo/oyag424
Vancouver
Chao CY, Tseng KY, Lin HC, Shih YH. Real-world comparative effectiveness of FOLFOX, FOLFIRI, and CapOx as second-line chemotherapy for advanced biliary tract cancer. The Oncologist. 2026;31(11). doi:10.1093/oncolo/oyag424
BibTeX
@article{Chao2026,
author = {Chao, Chun-Yang and Tseng, Kuan-Yu and Lin, Hsin-Chen and Shih, Yu-Hsuan},
title = {Real-world comparative effectiveness of FOLFOX, FOLFIRI, and CapOx as second-line chemotherapy for advanced biliary tract cancer},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {11},
doi = {10.1093/oncolo/oyag424}
}
EUVIMED